The phase 1b/2 EQUATE study demonstrated high clinical responses to itolizumab for patients with acute graft vs host disease.
The phase 1b/2 EQUATE study (NCT03763318) of first-line itolizumab (ALZUMAb) for grade 3 to 4 acute graft vs host disease showed promising rates of clinical response and a favorable safety profile, according to a presentation from the 2021 American Society of Hemaotlogy Annual Conference.
“Itolizumab is a monoclonal antibody that targets the CD6 receptor, which is a co stimulatory receptor expressed on CD4 and CD8 T effector (Teff) cells and modulates their activity and trafficking,” John Koreth, MBBS, DPhil, director of Translational Research and Stem Cell Transplantation, senior physician, and associate professor of medicine at Harvard Medical School, said during the presentation of findings from the ongoing open-label U.S.-based 3+3 dose-escalation study. “It is a first-in-class antibody that leads to the shedding of CD6 from the surface of these pathogenic T effectors, converting them to a relatively non-pathogenic, more akin to T-reg immunophenotype.”
The investigators evaluated 25 adult patients with grade 3-4 aGVHD who initiated steroid treatment within 7 days prior to their first dose of itolizumab. They were administered the treatment intravenously every 2 weeks for 5 doses on days 1, 15, 29, 30, 43, and 57.
Four patients received 0.4 mg/kg of itolizumab, while 9 received 0.8 mg/kg, and 9 received 1.6 mg/kg. Median follow-up was 146 days (range: 12-355). The investigators’ primary endpoints were safety, tolerability, and optimal dose levels. Secondary endpoints were pharmacokinetic/dynamic (PK/PD) effects (change in CD6 surface expression on CD4+ cells), and clinical activity.
“The baseline demographics across the 25 patients on this study are broadly comparable across cohorts. All but one subject had grade 3-4 severe aGVHD, per study intent, this was naturally dominated by the presence of lower cut involvement,” Koreth said.
A majority of patients had Minnesota High Risk Scores (76%), and 96% had an Ann Arbor biomarker scores of 2 or 3. Patients were mostly male (64%), White (84%), and had an average age of 55. In terms of the patients’ primary disease, 10 patients had acute myeloid leukemia (AML), 5 had myelodysplastic syndromes (MDS), and 10 had other types (not listed).
Most patients’ graft source was in their peripheral blood (92%), while for 2 patients, it was from their bone marrow.
Treatment-emergent adverse events (AEs) were experienced in 96% of patients. Serious AEs occurred in 64% of patients (n=16), only 2 of which were considered to be treatment related. One of these was a dose-limiting toxicity AE with sepsis.
There were 8 patients with AEs that led to death, however none of which were considered related to the study treatment. A dose-limiting toxicity AE was experienced by 1 patient, and discontinuation for 6 patients (24%). AEs that were grade 3 or higher were experienced in 80% of patients.
Itolizumab induced a significant early reduction (by 24 hours) in the cell surface expression of CD6 on immune effector cells. At 0.4 mg/kg, CD6 trended toward baseline by day 15. This was also sustained through the 15 days of initial treatment for the 2 high dose levels (0.8 and 1.6 mg/kg), with CD6 remaining significantly reduced (p<0.0001). By day 15, there was an observed decrease in the T-cell activation marker PD-1 on Teff cells. Investigators saw that among the 2 high dose levels, itolizumab increased the ratio of Treg to Teff cells.
All patients had early responses to itolizumab, with an overall response rate (ORR) of 71% and 50% of patients achieving a complete response (CR) by day 15. By day 29, 52% of patients had a CR and there was an ORR of 64%.
For patients who received itolizumab within 72 hours of steroids (n=18), 61% had CR and there was a 67% ORR.
Six-month outcomes (reported in 22 patients) revealed that responses were sustained in long-term follow-up. Eleven patients had durable responses (50%), all of which were CRs. Of the cohort, 64% were alive at the 6-month point.
“Notably, 12 of 14 responders were alive through day 169, as compared to only 2 of 8 non-responders,” Koreth highlighted.
First-line itolizumab treatment showed high rates of clinical responses, and dose-dependent reductions of CD6 expression on CD4+ T cells and an increase in the Treg to Teff cell ratio at the higher dose levels — which are being further explored —are consistent with the mechanism of action.
“Itolizumab was well-tolerated across all doses, especially given the context of a sick and severe cGVHD population,” Koreth concluded. “…We believe itolizumab offers a favorable benefit risk profile that supports its evaluation in future studies.”
Kireth J, Ritz J, Chinn L, et al. Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. Presented at the 63rd American Society of Hemaotlogy Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Virtual. Abstract 2891. https://bit.ly/3DSvbV5